NCT02963909View on ClinicalTrials.gov

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2016

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions

Zika Virus Infection

Interventions

BIOLOGICAL

IXIARO

An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).

OTHER

Placebo

0.9% Sodium Chloride 5 mcg

BIOLOGICAL

YF Vax 17D Strain

A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.

BIOLOGICAL

Zika Virus Purified Inactivated Vaccine (ZPIV)

Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.

Trial Locations (1)

20910-7500

Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02963909 - A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. | Biotech Hunter | Biotech Hunter